Novel product launches to reinvigorate acne treatment market by 2018

The acne therapeutics market value will undergo steady growth by 2018, increasing from $2.3 billion in 2012 to more than $2.8 billion by the end of the forecast period, representing a compound annual growth rate (CAGR) of 3.9%.

According to a new report from research and consulting firm GlobalData, within the six major markets (6MM) – the USA, France, Germany, Italy, Spain and the UK – the substantial majority of sales will come from the USA, which will retain its leading position in the global acne treatment arena and command 92% of the market in 2018, up slightly from 91% in 2012.

Heather Leach, GlobalData’s analyst covering Immunology, says: “The forthcoming market expansion can be attributed to the highly anticipated launches of AndroScience’s ASC-J9 and Photocure’s [PHO: OL] Visonac (methyl aminolevulinate) in 2017. The continued uptake and success of [now Nestle subsidiary] Galderma’s Epiduo (adapalene and benzoyl peroxide), with its label expansion into the pediatric population and launch of the Epiduo TAP program to improve patient compliance, will also prove a key driver behind the growth.”